Compare IPDN & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPDN | NVNO |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | United States | United States |
| Employees | N/A | 37 |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 7.2M |
| IPO Year | 2012 | N/A |
| Metric | IPDN | NVNO |
|---|---|---|
| Price | $1.30 | $10.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 119.4K | 13.6K |
| Earning Date | 03-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,054,219.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.96 | $0.30 |
| 52 Week High | $12.39 | $12.85 |
| Indicator | IPDN | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 54.68 |
| Support Level | $1.10 | $0.49 |
| Resistance Level | $1.98 | $12.69 |
| Average True Range (ATR) | 0.13 | 1.01 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 76.58 | 43.20 |
Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates majority of its revenue from TalentAlly Network Segment.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.